In parallel, we conducted a phase II clinical trial evaluating the combination of danvatirsen and checkpoint blockade in cancers that have previously demonstrated efficacy with STAT3 blockade: PDAC, NSCLC and CRC.6, 9. Here, STAT3 is linked to colorectal carcinoma.